Question · asked by 1 review
Low molecular weight heparin and idraparinux vs usual care: All‐cause mortality
- Population
- people > 18 years of age with a diagnosed deep vein thrombosis
- Intervention
- Low molecular weight heparin and idraparinux
- Comparison
- usual care
- Outcome
- All‐cause mortality
The review found no eligible studies for this question.
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Low molecular weight heparin and idraparinux vs standard therapy All‐cause mortality · people > 18 years of age with a diagnosed deep vein thrombosis The review found no eligible studies for this question. Pentasaccharides for the treatment of deep vein thrombosis (2017) · Cochrane Headline outcomes only | no estimate extracted | Not reported | No studies found |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Pentasaccharides for the treatment of deep vein thrombosis 2017 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.